This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 15

[Docket No. FDA–2014–N–1168]

Generic Drug User Fee Amendments of 2012; Public Hearing on Policy Development; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification of public hearing; request for comments.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public hearing to solicit public comment on certain topics related to implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA), and the GDUFA Commitment Letter that accompanies the legislation. The public hearing also will provide an opportunity for public input on future policy priorities. FDA is seeking participation in the public hearing and written comments from all interested parties, including, but not limited to, regulated industry, consumers, patients, caregivers, health care professionals, and patient groups.

DATES: The public hearing will be held on September 17, 2014, from 9 a.m. to 5 p.m. The public hearing may be extended or may end early depending on the level of public participation. Submit electronic or written requests to make oral presentations at the hearing by September 3, 2014. Electronic or written comments will be accepted after the hearing until October 13, 2014.

ADDRESSES: The public hearing will be held at the College Park Marriott Hotel and Conference Center, 3501 University Blvd., East, Hyattsville, MD 20783.

Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Identify all comments with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:
Shaniece Bowens, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1611, 240–402–7923, email: shaniece.bowens@fda.hhs.gov; or Connie Wisner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1674, 240–402–7946, email: connie.wisner@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background


On July 9, 2012, GDUFA was signed into law by the President to help speed the delivery of safe and effective generic drugs to the public and to reduce costs to industry. Under GDUFA, FDA agreed to certain obligations as laid out in the GDUFA Commitment Letter that accompanies the legislation. To support these obligations, FDA is developing numerous guidance documents. Thus far, FDA has developed the following draft guidances for industry:

1. ANDA Submissions—Content and Format of ANDAs
2. ANDA Submissions—Refuse to Receive for Lack of Proper Justification of Impurity Limits

Identify all comments with the docket number found in brackets in the heading of this document.

II. Purpose and Scope of the Public Hearing

A. GDUFA Implementation: Draft Guidance Documents

The purpose of this public hearing is to (1) solicit public comment on the five draft guidance documents described in section I that FDA has issued to facilitate implementation of GDUFA and (2) recommend future policy priorities, including recommendations for additional guidance topics to facilitate GDUFA implementation. We are soliciting comments from interested members of the public, including industry, consumers, patient groups, caregivers, and health care professionals, on the following topics related to GDUFA implementation guidelines:

1. Are there comments on the five draft guidelines described in section I?
2. Are there GDUFA implementation issues related to the five draft guidelines described in section I that have not been addressed?
3. What other GDUFA implementation topics need the development of guidance?
4. Are there any topics or issues related to generic drug development other than those related to GDUFA implementation that need the development of guidance?

B. GDUFA Implementation Related to Generic Drug Exclusivity

Another purpose of this hearing is also to solicit feedback on issues that may arise in FDA’s consideration of 180-day exclusivity provided for in section 505(j)(5)(B)(iv) of the FD&C Act. Timing of ANDA approval is directly affected by an applicant’s eligibility for 180-day exclusivity, and thus FDA’s consideration of any issues related to 180-day exclusivity is a component of approval actions. FDA decisions regarding 180-day exclusivity are fact-specific, and the facts that have the potential to determine eligibility for exclusivity may shift up to the time when an ANDA that is eligible for 180-day exclusivity, or another ANDA...
for each strength of a Reference Listed Drug submitted for which there is not already an approved ANDA at the time of submission, to a more narrow definition under which only ANDAs that contain a paragraph IV certification and qualify as a “first applicant” under section 505(j)(5)(B)(iv)(II)(bb) of the FD&C Act would be designated as a first generic eligible for expedited review. In addition, several stakeholders have indicated that depending on the criteria FDA applies, first generic status could or should change over time based on other external factors, for example, withdrawal or rescission of approval of another applicant’s ANDA, or shifts in the patent or exclusivity landscape (for example, an unsuccessful patent challenge).

In order to meet the goals in the GDUFA Commitment Letter with respect to expedited ANDA review, we will be prioritizing ANDA review consistent with the recently issued Manual of Policies and Procedures (MAPP) 5240.3 Rev. 1: Prioritization of the Review of Original ANDAs, Amendments, and Supplements, and MAPP 5200.4: Criteria and Procedures for Managing the Review of Original ANDAs, Amendments and Supplements. In order to meet the goals of the GDUFA Commitment Letter related to first generics in particular, in a manner that best effectuates the intent of the negotiators, we are seeking comment on the following questions:
1. What specific criteria should FDA apply to identify an ANDA as a first generic eligible for expedited ANDA review?
2. Are there other topics related to first generics eligible for expedited review on which you would like to comment?

III. Attendance, Registration, and Presentations

Attendance is free and on a first-come, first-served basis. We recommend that you register early because seating is limited.

If you wish to attend the hearing and/or make an oral presentation at the hearing, please register and/or send a request for oral presentation by email to GenericDrugPolicy@fda.hhs.gov by September 9, 2014. Persons registered to make an oral presentation should check in before the hearing and are encouraged to arrive early to ensure the designated order of presentation times. If you need special accommodations because of a disability, please contact Shaniece Bowens or Connie Wisner (see FOR FURTHER INFORMATION CONTACT) at least 7 days before the hearing.

IV. Notice of Hearing Under 21 CFR Part 15

The Commissioner of Food and Drugs is announcing that the public hearing will be held in accordance with part 15 (21 CFR part 15). The hearing will be conducted by a presiding officer, who will be accompanied by FDA senior management from the Office of Generic Drugs and other relevant Agency components. Under § 15.30(f), the hearing is informal and the rules of evidence do not apply. No participant may interrupt the presentation of another participant. Only the presiding officer and panel members may question any person during or at the conclusion of each presentation (§ 15.30(e)). Public hearings under part 15 are subject to FDA’s policy and procedures for electronic media coverage of FDA’s public administrative proceedings (21 CFR part 10, subpart G) (§ 10.203(a)). Under § 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA’s public administrative proceedings, including presentations by participants. The hearing will be transcribed as stipulated in § 15.30(b).
SUMMARY: BOEM is seeking comments and information regarding its effort to update its regulations and program oversight for Outer Continental Shelf (OCS) financial assurance requirements. When BOEM’s existing bonding regulations were originally drafted and first implemented, the principal risks associated with OCS leases were non-payment of rents and royalties, noncompliance with laws and regulations, and potential problems due to bankruptcy. While potentially significant, such risks were generally well-known and of limited complexity, size and scope.

Due to increasingly complex business, functional, organizational and financial issues and vast differences in costs associated with expanded and varied offshore activities, BOEM has recognized the need to develop a comprehensive program to assist in identifying, prioritizing, and managing the risks associated with industry activities on the OCS. BOEM intends to design and implement a more robust and comprehensive risk management, financial assurance and loss prevention program to address these complex issues and cost differences associated with offshore operations. To do so, BOEM is seeking stakeholder comments regarding various risk management and monitoring activities pertaining to financial risks to taxpayers that may result from activities on the OCS. This notice specifically discusses the bonding and financial assurance program for BOEM’s offshore oil and gas program. However, we also welcome the submission of comments on the analogous bonding and financial assurance program for BOEM’s offshore renewable energy and hard minerals programs.

BOEM currently requires lessees to provide performance bonds and/or one of various alternative forms of financial assurance to ensure compliance with the terms and conditions of leases, Rights-of-Use and Easements (RUEs) and Pipeline Rights-of-Way (ROWs). BOEM is seeking comments on who is best suited to mitigate risks and whether the correct parties are providing guarantees and other forms of financial assurance, as well as whether, or to what extent, the current forms of financial assurance are adequate and appropriate.

Because costs and damages associated with oil spill financial responsibility (OSFR) are covered separately in the regulations, which is the subject of another proposed rulemakings on BOEM’s regulatory agenda, BOEM is not soliciting comments on those regulations and their associated risk mitigation measures at this time.

DATES: BOEM will consider all comments received by midnight of October 20, 2014. BOEM cannot commit to considering comments received after midnight on October 20, 2014.

ADDRESSES: You may submit comments on this ANPR using the Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions on the Web site for submitting comments. Please use Regulation Identifier Number (RIN) 1010–AD83 as an identifier in your message. See also the “Public Comment Policy” paragraph under the SUPPLEMENTARY INFORMATION section below.

FOR FURTHER INFORMATION CONTACT: For information regarding BOEM’s comprehensive risk management, financial assurance, and loss prevention program or the major topics of this ANPR, contact Terry Scholten at terry.scholten@boem.gov (504–810–2078) or Donna Dixon at Donna.Dixon@boem.gov (504–731–1527), or by mail at 1201 Elmwood Park Blvd., GM364D, New Orleans, LA 70123. For issues related to the rulemaking process or timetable, contact Peter Meffert at peter.meffert@boem.gov (703–787–1610), or by mail at 381 Elen St., Herndon, VA 20170.

SUPPLEMENTARY INFORMATION:

Public Availability of Comments: Before including your address, phone number, email address, or other personal identifying information in your comments, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you may ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so under Federal law.